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Summary.-The data from a dilution assay can be used not only to form an estimate of the TD50 (or log TD50), but also to throw light on the transplantation kinetics of tumours. Transplantation "by single cells" is the simplest sort of kinetics, and some tumours, of which we have given two examples, will transplant by single cells.
Other tumours consistently transplant with anomalous kinetics-i.e. non-singlecell. A sensitive statistical test for single-cell behaviour has been developed, and we give three examples of tumours that clearly fail the test. The mechanism by which these anomalous tumours depart from single-cell behaviour is unknown, but we suggest an approximate statistical analysis for their assay.
THE technique of dilution assay was first applied to malignant cells (of a mouse leukaemia) by Hewitt and Wilson (1959) . Since then the technique has been applied to a wide variety of tumours by Berry and Andrews (1961) , Reinhold (1967) and by many others. In these studies the assays have usually merely provided data from which the authors deduce survival curves, anoxic fractions, or other information of exclusively radiobiological interest. However in the wider context of general tumour biology, dilution assays can throw light on the transplantation kinetics of tumour cells, and this may be as important for the understanding of the process of metastasis as, for example, the " cell-loss factor " has been for the understanding of the process of tumour growth.
In a dilution assay, a cell-suspension is prepared and the density of morphologically intact tumour cells is estimated by counting. Inocula of different sizes are prepared by serial dilution and injected into recipient animals. A single animal can provide several subcutaneous sites for injection, or one intraperitoneal site. After a sufficient period of observation the number of takes and failures to take for each site of inoculum is scored. The characteristic feature of this type of assay is that each site (or animal) shows only whether its inoculum produced a tumour or not; the number of cells contributing to a take is not shown. The name " dilution assay" is therefore inept (serial dilutions are an essential part of most biological assays), but this is the term generally used and its limits are understood.
The results of a dilution assay can be used to calculate a TD50 (the number of tumour cells required to produce 5000 takes), and TD50's are commonly interpreted on the theory that:
(1) Some of the tumour cells are clonogenic.
(2) An inoculum produces a take if, and only if, it contains at least one clonogenic cell.
(3) Any non-clonogens in the inoculum have no influence on the outcome (take or no take).
A tumour that obeys these three assumptions will be described here as transplanting " by single cells ". This is, of course, the simplest possible sort of transplantation kinetics, and leads to a simple interpretation of the TD50 as that inoculum size which contains 0-693 clono- (1) where e is the base of natural logarithms. For transplantation by single cells, the average number of clonogens (m) will be proportional to the inoculum size (z):
(2) m = k.z and this can be rewritten as log m = log k + log z In the present context, z will be a number of morphologically intact tumour cells, so that k will be a clonogenic fraction.
Finney shows that it is best to work in terms of the logarithm of inoculum size (as in equation 3), and hence to derive an estimate of the logarithm of the clonogenic fraction: the logarithm has a nearly normal error-distribution, whereas a direct estimate of k would have a highly nonnormal one.
Finney's method is an iterative one for arriving at the maximum likelihood estimate of log k, together with its standard log. inoculum size 
error and a chi-square value for deviations from the single-cell curve. In the singlecell case the TD50 is that inoculum size which contains 0-693 (loge2) clonogens, so that it is very straightforward to pass from an estimate of the log clonogenic fraction to an estimate of the log TD50. It is almost as straightforward to pass from natural logarithms to common (base ten) logarithms: such conversions from the unfamiliar to the familiar are a great help to the non-mathematician. Here the conversions will be assumed: all results will be quoted in terms of log TD50's, and all logarithms will be to base ten. Fig. 1 shows the single-cell curve fitted by Finney's method to pooled data from 10 assays of one transplantable tumour, the CBA ' NT ', which is a poorly differentiated carcinoma. The calculation gives a log TD50 of 3-84 with s.e. 0-038, and a chi-square for deviations from the single-cell curve of 25 7 with 31 degrees of freedom (d.f.). Fig. 1 gives a visual impression of a good fit between curve and data, and the low value of chi-square confirms that the fit is good; but if the numbers of sites and the numbers of takes in all the experiments had all been ten times larger the figure would have looked the same, and the calculation would have shown, correctly, a highly significant value of chi-square.
The statistical analysis illustrated by Fig. 1 shows not only that the tumour ' NT ' transplants by single cells, but also that its log TD50 has remained effectively constant over 13 months and 25 serial passages. For if the log TD50 had not remained constant, the chi-square for the pooled data would have been significantly inflated over the sum of the chi-squares for the assays analysed separately. Here the difference (pooled-separate) is a chisquare of 13-3, which with 9 d.f. is not significant. a keratinizing squamous carcinoma which has been fully described by Hewitt, Chan and Blake (1967 Random errors of counting and dilution will of course add to the variance of estimate of the log TD50 derived from an assay. The figures given here neglect this source of variation, but an estimate can be formed that it at worst adds 10% to the variance. The effect on the assay slope is negligibly small.
It is possible to alter the log TD50's of these tumours by assaying them in recipients given whole-body irradiation, and by adding lethally irradiated cells to each inoculum. Such treatments can change the log TD50 by up to 3 logs (a factor 1000), and their effects will be discussed in another paper; it is here relevant that they do not detectably alter the transplantation kinetics, whether these are single-cell or anomalous.
Each tumour thus seems to have its own characteristic and consistent transplantation kinetics, and this may well apply generally. The leukaemia studied by Hewitt and Wilson (1959) and the ascites tumour studied by Berry and Andrews (1961) both transplant by single cells; and the rat rhabdomyosarcoma of Reinhold (1967) transplants with an anomalously low slope.
Of the 5 tumours discussed here, the 2 carcinomata transplant by single cells and the 3 sarcomata transplant anomalously. The association is probably misleading, for a small number of assays of a sixth tumour (the WHT Sq. Ca. ' G ') point to a lower slope than the single-cell one, but give insufficient data for more than this negative statement.
Immunological factors can be invoked to account for anything from rejection of a tumour to enhancement of its growth. It is therefore tempting to explain anomalous transplantation kinetics as an immunological manifestation. There are, however, reasons against accepting such an explanation. These tumours are all spontaneous, and arose in mouse strains of low cancer incidence. Viruses and chemical carcinogens, which can produce definitely antigenic tumours, played no part here. The assays were done in mice of the same strain, and indeed the same colony as that in which the tumour arose and had always been transplanted; in these circumstances we have never succeeded in altering a TD50 by " immunizing " the recipients, and we have never seen spontaneous remission.
The transplantation kinetics of the anomalous tumours thus remain a mystery. It does not seem to be possible to account convincingly for the findings on the basis of variability in the recipient mice, technical error, or immunological incompatibility between the tumours and their syngeneic hosts. The assays can be analysed by a method which implies that the number of clonogens in an inoculum varies as a fractional power of its size: the implication is incredible, but the approximation is useful.
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